Results 231 to 240 of about 54,431 (288)

Analysis of the cytotoxicity and bioactivity of CeraSeal, BioRoot™ and AH Plus® sealers in pre-osteoblast lineage cells. [PDF]

open access: yesBMC Oral Health
de Almeida-Junior LA   +7 more
europepmc   +1 more source

Social voice judgement is dyadic: Acoustic typicality and interpersonal similarity interact

open access: yesBritish Journal of Psychology, EarlyView.
Abstract The formation of social first impressions from voices is a central component of everyday social interactions. While past research has primarily investigated the effect of bottom‐up voice acoustic on social voice judgements, here we widen the perspective and investigate how bottom‐up acoustic and top‐down interpersonal similarity interactively ...
Selma Bruggisser   +2 more
wiley   +1 more source

Feasibility and workflow analysis of confocal microscopy in robot‐assisted prostatectomy

open access: yesBJU International, EarlyView.
Objectives To assess the diagnostic accuracy, workflow feasibility, and downstream compatibility of fluorescence confocal microscopy (Histolog® Scanner [HS]; SamanTree Medical SA, Lausanne, Switzerland) compared with frozen section (FS) for intraoperative margin evaluation (IME) during nerve‐sparing robot‐assisted radical prostatectomy (RARP). Patients
Kristijan Skok   +11 more
wiley   +1 more source

Comparative bioactivity and immunomodulatory potential of the new Bioroot Flow and AH Plus Bioceramic sealer: An in vitro study on hPDLSCs. [PDF]

open access: yesClin Oral Investig
Sanz JL   +6 more
europepmc   +1 more source

AMPK‐mediated prevention of vascular dysfunction with metformin: Experimental and population‐based evidence

open access: yesBritish Journal of Pharmacology, EarlyView.
Angiotensin II induces vascular inflammation, senescence, extracellular matrix (ECM) degradation and endothelial dysfunction, thus impairing SK+/IK+ channel function and reducing endothelial‐dependent hyperpolarisation (EDH). Metformin activates AMPK, increasing SK+/IK+ channel function and restoring vasorelaxation.
Soroush Mohammadi Jouabadi   +10 more
wiley   +1 more source

Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐TAIL‐2

open access: yesCancer Science, EarlyView.
BLURB FOR ETOC: The J‐TAIL‐2 study (NCT04501497) evaluated the efficacy and safety of atezolizumab, an anti‐programmed death‐ligand 1, plus chemotherapy in patients with non‐small cell lung cancer (NSCLC) and extensive‐stage small cell lung cancer (ES‐SCLC) in real‐world settings.
Yasushi Goto   +19 more
wiley   +1 more source

Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes

open access: yesCancer Science, EarlyView.
Afatinib and osimertinib showed broadly comparable survival outcomes as first‐line therapy for NSCLC with uncommon EGFR mutations. Treatment may be individualized by mutation subtype, while adding immune checkpoint inhibition to platinum doublet after EGFR‐TKI showed no clear benefit.
Yutaro Nagano   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy